These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31420504)

  • 1. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
    Ayres JD
    PDA J Pharm Sci Technol; 2018; 72(6):626-639. PubMed ID: 30158238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial.
    Timmons CL; Liu CY; Merkle S
    PDA J Pharm Sci Technol; 2017; 71(5):379-392. PubMed ID: 28512178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scientific basis for visible particle inspection.
    Knapp JZ
    PDA J Pharm Sci Technol; 1999; 53(6):291-302. PubMed ID: 10754727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing Container Closure Integrity and Aesthetics for a Robust Aseptic or Sterile Vial Packaging System.
    Oni Y; Song X; Schrader M; Kulshrestha A; Franck J; Asselta R; Flores-Crespo C; Mantri RV
    PDA J Pharm Sci Technol; 2019; 73(6):572-587. PubMed ID: 31101708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing.
    Weber J; Hauschild J; Ijzerman-Boon P; Forng RY; Horsch J; Yan L; Prasad A; Henry RB; Claassen M; Villari P; Shereefa S; Wyatt J; Bolden JS; Pycke JT; Dassu D
    PDA J Pharm Sci Technol; 2019; 73(2):121-134. PubMed ID: 30361285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach.
    Langille SE
    PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Particles in Parenteral Drug Raw Materials.
    Lee K; Lankers M; Valet O
    PDA J Pharm Sci Technol; 2018; 72(6):599-607. PubMed ID: 29669816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
    Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K
    J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particulate matter in injectable drug products.
    Langille SE
    PDA J Pharm Sci Technol; 2013; 67(3):186-200. PubMed ID: 23752747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.